Results 281 to 290 of about 1,861,365 (381)
NMDAR‐Antibody Encephalitis Diagnosed With Primary Central Nervous System Lymphoma: A Case Series
ABSTRACT N‐methyl‐D‐aspartate receptor‐antibody encephalitis (NMDAR encephalitis) is one of the most common forms of autoimmune encephalitis, with a paraneoplastic relationship described in approximately 38%. Primary central nervous system lymphoma (PCNSL) is a rare hematologic malignancy that is not often considered as the underlying neoplasm in this ...
Soo Hyun Ahn+4 more
wiley +1 more source
Cellular senescence: mechanisms and relevance to cancer and aging. [PDF]
Yamauchi S, Takahashi A.
europepmc +1 more source
C/EBPβ cooperates with RB:E2F to implement RasV12-induced cellular senescence
Thomas Sebastian+4 more
openalex +1 more source
Functional Diversity of Human Protection of Telomeres 1 Isoforms in Telomere Protection and Cellular Senescence [PDF]
Qin Yang+8 more
openalex +1 more source
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Bennett G. Childs+3 more
semanticscholar +1 more source
ABSTRACT Objective Despite the availability of effective therapies for Multiple Sclerosis (MS), the unpredictable nature of disease progression and the variability in individual treatment outcomes call for reliable biomarkers. This pilot study aims to investigate the potential of plasma circulating microRNAs (miRNAs) as predictive biomarkers for ...
Fortunata Carbone+19 more
wiley +1 more source
Therapeutic effects of PDGF-AB/BB against cellular senescence in human intervertebral disc. [PDF]
Zhang C+6 more
europepmc +1 more source
p38 MAPK inhibits nonsense-mediated RNA decay in response to persistent DNA damage in noncycling cells [PDF]
Cheruiyot, Abigael+5 more
core +2 more sources
Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan+8 more
wiley +1 more source